Oct 12, 2020 / 12:00PM GMT
Operator
Good day, everyone. Welcome to the Bristol-Myers Squibb event at UEGW. Today's call is being recorded.
At this time, I'd like to turn the conference over to Mr. Tim Power, Vice President, Investor Relations. Please go ahead, sir.
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR
Great. Thanks, Alan, and good morning, everyone. Joining me for today's presentation are Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development; and Chris Boerner, our Chief Commercialization Officer. And also on today's call is Giovanni Caforio, our Board Chair and Chief Executive, who will be joining Samit and Chris for the Q&A.
As a reminder, slides for today's presentations are available on the Investor Relations section of bms.com. And I'll refer you to Slide 2 of today's presentation for our legal disclosures.
And with that, I'll hand over the call to Samit, starting on Slide 3.
Samit Hirawat - Bristol-Myers Squibb Company - Executive VP & Chief Medical Officer of Global Drug
Bristol-Myers Squibb Co Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Ulcerative Colitis at UEG Week 2020 Transcript
Oct 12, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers